Journal News

A tiny genetic tweak with big heart health implications

Nipuna Weerasinghe
Jan. 2, 2024

Heart disease remains a leading cause of death globally. A gene mutation found among members of the Amish community could pave the way for new treatments, a research team recently reported.

The scientists delved into plasma’s depths to understand how a specific mutation of a gene involved in posttranslational modification of proteins via covalently adding carbohydrates, a process known as glycosylation, can affect our plasma proteome, lipid levels and potentially heart health.

In a study recently published in the journal Molecular & Cellular Proteomics, Yunlong Zhao and a team of scientists from Regeneron Pharmaceuticals in New York and the University of Maryland focused on the B4GALT1 gene. This gene directs the synthesis of the enzyme beta-1,4-galactosyltransferase 1, or B4GALT1. This enzyme catalyzes the addition of ß-galactose sugar to core N-glycan structures during stepwise protein glycosylation in the Golgi apparatus.

Specifically, the researchers were interested in a naturally occurring mutation of B4GALT1 called N352S. This variant is exceedingly rare in the general population (fewer than one in 10,000 people have it), but it is found in about 12% of individuals in the Lancaster County, Pennsylvania, Amish community. The N352S mutation correlates with lower cardiovascular disease levels. The research team aims to understand how this variant alters B4GALT1 activity and how this affects levels of plasma glycoproteome and lipids, such as low-density lipoprotein cholesterol, which plays a role in atherosclerosis.

The team used plasma for a couple of reasons. “Plasma is an ideal starting point for our research. It can be directly drawn from individuals with this naturally occurring mutation and readily linked to other clinical indices,” Zhao said. “But it’s not just about convenience. Plasma contains proteins that regulate circulating lipid levels, making it relevant for their study.”

The team used tandem mass tag, or TMT, labeling proteomic and glycoproteomic approaches to look at proteins and their glycosylation patterns in plasma samples. They found that the N352S mutation primarily influences glycosylation patterns of plasma proteins without significantly altering the expression levels of most identified proteins, except the ones involved in the coagulation and immune response pathways.

“We are still in the process of fully understanding how the initial action leads to the final outcome,” Zhao said.

So, what does this mean for human health? The study highlights the potential of targeting glycosylation for treating heart diseases by regulating circulating lipid levels.

“While our findings are promising,” Zhao said, “it’s still too early to state that B4GALT1 could serve as a potential drug target, or that manipulating glycosylation could be a valid approach to treating atherosclerosis and cardiovascular disease.”

Zhao continued: “Currently, we are advancing our research through further validation studies using animal models and large-scale clinical sample analysis, aiming to confirm our initial findings and elucidate the underlying mechanisms, in collaboration with our partners. Our ultimate goal is to translate these findings into therapeutic value, but more research is needed before we can reach that point.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Nipuna Weerasinghe

Nipuna Weerasinghe holds a bachelor’s degree in chemistry from the University of Colombo, Sri Lanka, and a master’s degree in chemistry from the University of Arizona.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

From the journals: JLR
Journal News

From the journals: JLR

Dec. 13, 2024

Fixation method to quantify brain metabolites. Belly fat and liver disease crosstalk. Stopping heart diseases in schizophrenic patients. Read about the recent JLR papers on these topics.

Does a protein hold the key to Alzheimer’s?
Journal News

Does a protein hold the key to Alzheimer’s?

Dec. 10, 2024

Researchers in Maryland and Massachusetts team up to study how SORL1 promotes tau trafficking and seeding in cells that leads to the neurodegenerative disorder.

Cracking the recipe for perfect plant-based eggs
News

Cracking the recipe for perfect plant-based eggs

Dec. 8, 2024

It involves finding just the right proteins. With new ingredients and processes, the next generation of substitutes will be not just more egg-like, but potentially more nutritious.

MSU researchers leverage cryo-EM for decades-in-the-making breakthrough
News

MSU researchers leverage cryo-EM for decades-in-the-making breakthrough

Dec. 7, 2024

Lee Kroos and Ben Orlando have reported the first high-resolution experimentally determined structures of the intramembrane protease SpolVFB.

From the Journals: MCP
Journal News

From the Journals: MCP

Dec. 6, 2024

Rapid and precise SARS-CoV-2 detection using mass spec. Mapping brain changes from drug addiction. Decoding plant osmotic stress response. Read about recent MCP papers on these topics.

What seems dead may not be dead
Award

What seems dead may not be dead

Dec. 4, 2024

Vincent Tagliabracci will receive the Earl and Thressa Stadtman Distinguished Scientist Award at the ASBMB Annual Meeting, April 12–15 in Chicago.